[A comparative double-blind trial of HSR-902 and butylscopolamine bromide for relieving colic in ureteral stone patients].
The clinical efficacy and safety of HSR-902 (tiquidium bromide, Thiaton) in patients with spastic pain caused by ureteral stones were evaluated in a double blind comparative trial. A daily dose of 30 mg HSR-902 or 60 mg butylscopolamine bromide as a control drug was orally administered for 7 days. With either drug marked improvement of spastic pain was observed. The time to obtain relief from spastic pain and utility rating were significantly more excellent with HSR-902 than with butylscopolamine bromide. With all other parameters used no significant difference was observed between the two drugs. Mild adverse effects such as abdominal discomfort and constipation were observed in 2 of the 87 cases in the butylscopolamine bromide group but none of the 83 cases in the HSR-902 group. Taking efficacy and safety of the treatment into consideration, no significant difference was observed in usefulness between the two drugs, and we were able to confirm the usefulness of HSR-902 for relief from spastic pain caused by ureteral stones.
D000328:Adult; D002086:Butylscopolammonium Bromide / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003085:Colic / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005730:Ganglionic Blockers / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011807:Quinolizines / Q000627:therapeutic use*; D014514:Ureteral Calculi / Q000188:drug therapy*
D005730:Ganglionic Blockers; D011807:Quinolizines; D002086:Butylscopolammonium Bromide; C030950:thiaton